Fusion Antibodies PLC
LSE:FAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Dangee Dums Ltd
NSE:DANGEE
|
IN |
|
N
|
Nexam Chemical Holding AB
STO:NEXAM
|
SE |
|
O
|
Optowide Technologies Co Ltd
SSE:688195
|
CN |
|
R
|
Reino Capital SA
WSE:RNC
|
PL |
|
Investor AB
STO:INVE B
|
SE |
|
Holon Co Ltd
TSE:7748
|
JP |
Fusion Antibodies PLC
Research & Development
Fusion Antibodies PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Research & Development
-£366k
|
CAGR 3-Years
20%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Oxford Biodynamics PLC
LSE:OBD
|
Research & Development
-£615k
|
CAGR 3-Years
-5%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Research & Development
-£97.7m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genedrive PLC
LSE:GDR
|
Research & Development
-£4.5m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-3%
|
|
|
hVIVO PLC
LSE:HVO
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Fusion Antibodies PLC
Glance View
Fusion Antibodies Plc engages in the provision of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company is headquartered in Belfast, Northern Ireland and currently employs 54 full-time employees. The company went IPO on 2017-12-18. The firm offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The principal activity of the Company is the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The Company’s services include discovery, engineering and supply. Discovery services includes creation, screening and sequencing of monoclonal antibodies for therapeutic and diagnostic applications. Engineering services includes maximizing the performance of an antibody drug including CDRx humanization, Antibody Developability by Design (ADDTM) and RAMP. Supply services includes the production of material for clinical production or further research, including cGMP ready stable cell line development and transient expression.
See Also
What is Fusion Antibodies PLC's Research & Development?
Research & Development
-366k
GBP
Based on the financial report for Sep 30, 2025, Fusion Antibodies PLC's Research & Development amounts to -366k GBP.
What is Fusion Antibodies PLC's Research & Development growth rate?
Research & Development CAGR 5Y
-6%
Over the last year, the Research & Development growth was -48%. The average annual Research & Development growth rates for Fusion Antibodies PLC have been 20% over the past three years , -6% over the past five years .
